Adverse consequences of accelerated neonatal growth: cardiovascular and renal issues

Umberto Simeoni1, Isabelle Ligi, Christophe Buffat

  • 1Division of Neonatology, Hôpital la Conception, Assistance Publique-Hôpitaux de Marseille, 147 Boulevard Baille, 13385, Marseille, France. umberto.simeoni@ap-hm.fr

Insights

Low birth weight is linked to adult cardiovascular and metabolic diseases. This review explores how early life factors, including kidney development and postnatal nutrition, influence chronic kidney disease risk.

Area of Science:

  • Developmental biology
  • Nephrology
  • Public health

Background:

  • Birth weight is inversely associated with adult cardiovascular and metabolic disease risk.
  • Low birth weight is increasingly implicated in the development of chronic kidney disease (CKD).
  • Renal factors, particularly nephron endowment, are crucial in programming hypertension and renal disease.

Purpose of the Study:

  • To review the role of the kidney in the developmental origins of adult disease theory.
  • To focus on the long-term effects of postnatal growth and nutrition on renal and cardiovascular health.
  • To examine the kidney as both a mechanism and a target in early-life disease programming.

Main Methods:

  • Review of epidemiological and experimental studies, with a focus on rodent models.
  • Analysis of the "multihits" theory involving nephron endowment and postnatal growth.
  • Synthesis of current understanding on early-life influences on adult renal and metabolic functions.

Main Results:

  • Reduced nephron number, often seen in low birth weight, is an initial hit for adult disease.
  • Rapid postnatal growth can act as a second hit, exacerbating disease risk.
  • Experimental data highlight the long-term impact of postnatal nutrition and growth on renal and cardiovascular outcomes.

Conclusions:

  • The kidney plays a central role in the developmental origins of adult cardiovascular, metabolic, and renal diseases.
  • Early-life factors, including birth weight and postnatal nutrition, significantly program long-term kidney health.
  • Understanding these early-life influences is critical for preventing adult chronic diseases.

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...